论文部分内容阅读
激素补充治疗(HRT)可确切缓解妇科恶性肿瘤患者治疗后因雌激素缺乏引起的相关症状,但许多妇科恶性肿瘤的发生与女性激素尤其是雌激素密切相关,必须保证HRT在获益的同时不增加肿瘤的复发风险。目前认为,Ⅱ型子宫内膜癌、卵巢生殖细胞肿瘤、宫颈癌、外阴癌等为非性激素依赖肿瘤,应用HRT是安全的;虽然Ⅰ型子宫内膜癌和卵巢上皮性癌等为性激素依赖肿瘤,但至少目前没有证据支持HRT会影响患者的复发和预后。临床应用前要充分知情同意,并根据患者意愿和实际情况制订个体化方案。
Hormone replacement therapy (HRT) can definitely relieve the symptoms associated with estrogen deficiency after gynecological malignancies, but many gynecological malignancies are closely related to estrogen, especially estrogen. It is necessary to ensure that HRT can not benefit Increase the risk of tumor recurrence. Currently, type Ⅱ endometrial cancer, ovarian germ cell tumors, cervical cancer, vulvar cancer and other non-sex hormone-dependent tumors, the application of HRT is safe; although type Ⅰ endometrial cancer and ovarian cancer such as sex hormone-dependent tumors , But at least there is currently no evidence that HRT will affect patient relapse and prognosis. Before clinical application should be fully informed consent, and according to the wishes of patients and the actual situation to develop individualized programs.